26 November, 2024 in Investor Relations New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
01 November, 2024 in Investor Relations Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
